Could you tell me about the firm? Mr. Kennedy: AllSource is a firm that focuses on high-net-worth and ultra-high-net-worth families, and we specialize in alternative investments. We like to say we ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
BridgeBio could be an acquisition target, but current financial challenges and competition suggest a "Hold" rating until ...
The genomics industry is set for growth due to advancements in personalized medicine, diagnostics, and biotech innovations.
AbbVie ( ABBV 0.64%) is a leader in biopharmaceuticals with a product portfolio spanning multiple therapeutic areas, ...
(RTTNews) - BioXcel Therapeutics, Inc. (BTAI), Thursday announced a reverse stock split of 1-for-16 to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq ...
Caprock Group LLC purchased a new position in shares of iShares Biotechnology ETF (NASDAQ:IBB – Free Report) in the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 3,344 ...
2d
Stocktwits on MSNTonix Pharma Dominates Retail Biotech Buzz After 1-for-100 Reverse Split, Sentiment Turns Neutral Amid VolatilityTonix Pharmaceuticals saw its shares swing wildly between gains and losses on Wednesday morning as they started to trade ...
It was a busy week for the biotech sector as the fourth-quarter earnings season kicked in. While Regeneron REGN gained following the announcement, Amgen AMGN was in the red. Meanwhile, other pipeline ...
Bio-Techne Corp (NASDAQ:TECH) reported stronger-than-expected earnings for the second quarter of fiscal year 2024, with adjusted earnings per share (EPS) of $0.42, surpassing the forecasted $0.39.
Low-cost passive index investing (in the S&P 500 or Nasdaq 100) has been key to impressive results in recent years. However, ...
7d
Investor's Business Daily on MSNInvesting Action Plan: A Big Week For Biotechs, Pharma And Econ, Plus Amazon And AlphabetThe week's investing action plan includes a strong dose of pharma and biotech earnings, January econ reports, plus Amazon and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results